Trial Profile
A long-term safety of alemtuzumab in relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 22 Feb 2016 New trial record